Almirall secures 5th partnership
Enlarge image


Almirall secures 5th partnership

15.10.2012 - Patients in Australia and New Zealand will also receive Almirall's Aclidinium against the lung disease COPD. Invida is the licensing partner.

After the approval of Aclidinium by the European Commission in July and the following deal with Italian Menarini Group to commercialise the drug in most of Europe in July, Barcelona-based Almirall S.A. has inked a marketing partnership with Invida Holdings Private Limited, a member of the Menarini Group, to sell the drug on the fifth continent . Invida gains the commercial rights for Aclidinium in Australia and New Zealand, with the deal including both monotherapy and combination therapy (with Formoterol). Both treatments work against Chronic Obstructive Pulmonary Disease (COPD), where the drug relieves the tension in the muscles around the lungs to improve airflow.

COPD makes breathing difficult and is often caused by cigarette smoking. It is estimated that around 2 million people in Australia suffer from the disease, where it is the sixth most common cause of death among men and seventh among women, Almirall said. Financial details of the agreement have not been disclosed.  Eduardo Sanchiz, Chief Executive Officer of Almirall, states: "Together with Invida, we will be able to offer this novel therapy in Australia and New Zealand for COPD. With this new agreement Aclidinium, via partners or Almirall's own salesforce, now has access to over 80% of the COPD world market including the US, Japan, Korea and Europe, where we already have secured four license agreements in total." In Germany and Denmark, Aclidinium bromide is already on the market. It works as a long-acting inhaled muscarinic antagonist - sometimes referred to as an anticholinergic -, which has a long residence time at M3 receptors and a shorter residence time at M2 receptors. It is designed to be rapidly broken down in plasma into two major inactive metabolites, explaining its high topical efficacy but low propensity for systemic anticholinergic effects. When taken by inhalation, Aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction.   



26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • EVOCUTIS (UK)0.11 GBP22.22%
  • EPIGENOMICS (D)2.65 EUR17.26%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • SERODUS (N)2.18 NOK-18.35%
  • DEINOVE (F)5.14 EUR-17.63%


  • PLETHORA (UK)5.50 GBP91.0%
  • PROTHENA PLC (IE)75.31 USD46.2%


  • EPIGENOMICS (D)2.65 EUR-44.0%
  • EVOCUTIS (UK)0.11 GBP-26.7%


  • KARO BIO (S)37.90 SEK5314.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.60 EUR260.1%


  • BIOTEST (D)15.31 EUR-81.0%
  • NEOVACS (F)0.80 EUR-76.5%

No liability assumed, Date: 29.11.2015